Abstract: Compounds of formula I, wherein A is an optionally substituted five-membered unsaturated heterocyclic ring containing 1, 2, or 3 N, O, or S ring heteroatom(s) exhibit alpha2C antagonistic activity and are thus useful for the treatment of diseases or conditions of the peripheric or central nervous system.

Abstract: Compounds of formula I, wherein A is an optionally substituted five-membered unsaturated heterocyclic ring containing 1, 2, or 3 N, O, or S ring heteroatom(s) exhibit alpha2C antagonistic activity and are thus useful for the treatment of diseases or conditions of the peripheric or central nervous system.

Abstract: Compounds of formula I, wherein Ra and Rb are as defined in the claims, exhibit alpha2C antagonistic activity and are thus useful as alpha2C antagonists.

Abstract: Compounds of formula I, wherein A is an optionally substituted five-membered unsaturated heterocyclic ring containing 1, 2, or 3 N, O, or S ring heteroatom(s) exhibit alpha2C antagonistic activity and are thus useful for the treatment of diseases or conditions of the peripheric or central nervous system.

Abstract: Compounds of formula (I) wherein R1 to R8, A, B, Z1, and Z2 are as defined in the claims and pharmaceutically acceptable salts and esters thereof are disclosed. The compounds of formula (I) possess utility as androgen receptor antagonists (inhibitors) and/or cytochrome P450 monooxygenase 17?-hydroxylase/17,20-lyase (CYP17) inhibitors. The compounds are useful as medicaments in the treatment of cancer, particularly prostate cancer, and other androgen dependent conditions and diseases where androgen antagonism is desired.

Abstract: Compounds of formula (I) wherein R1 to R8, A, B, Z1, and Z2 are as defined in the claims and pharmaceutically acceptable salts and esters thereof are disclosed. The compounds of formula (I) possess utility as androgen receptor antagonists (inhibitors) and/or cytochrome P450 monooxygenase 17?-hydroxylase/17,20-lyase (CYP17) inhibitors. The compounds are useful as medicaments in the treatment of cancer, particularly prostate cancer, and other androgen dependent conditions and diseases where androgen antagonism is desired.

Abstract: A process for the preparation of a catalyst that is in the form of solid particles includes preparing a solution of a complex of a metal and an electron donor; adding to the solution solid material obtaining a suspension combining the suspension at a temperature of at least 50° C. with at least one transition metal compound resulting in a precipitation of the catalyst being in the form of a solid particle; and optionally separating the catalyst.

Abstract: The invention refers to a process for preparing a Group 2 metal/transition metal olefin polymerization catalyst component in particulate form for polymerizing olefins, especially ethylene or propylene or comonomers thereof.

Abstract: The invention refers to a process for preparing a Group 2 metal/transition metal olefin polymerisation catalyst component in particulate form free of conventional phthalate electron donors and the use thereof in a process for polymerising olefins.

Abstract: Process for the preparation of a catalyst being in the form of solid particles comprising the steps of preparing a solution of a complex of a metal which is selected from one of the groups 1 to 3 of the periodic table (IUPAC) and an electron donor by reacting a compound of said metal with said electron donor in an organic liquid reaction medium; adding to said solution solid material obtaining a suspension, said solid material does not comprise catalytically active sites, has a specific surface area below 500 m2/g, and has a mean particle size below 200 nm; combining said suspension at a temperature of at least 50° C.

Abstract: The invention refers to a process for preparing a Group 2 metal/transition metal olefin polymerization catalyst component in particulate form having improved polymerization properties due to the use of H2 during catalyst component preparation and the use of such catalyst components in a process for polymerizing olefins.

Abstract: The invention refers to a process for preparing a Group 2 metal/transition metal olefin polymerisation catalyst component in particulate form for polymerising olefins, especially ethylene or propylene or comonomers thereof.

Abstract: The invention refers to a process for preparing a Group 2 metal/transition metal olefin polymerisation catalyst component in particulate form free of conventional phthalate electron donors and the use thereof in a process for polymerising olefins.

Abstract: Catalyst in form of solid particles, wherein the particles—have a specific surface area of less than 20 m2/g, comprise a transition metal compound which is selected from one of the groups 4 to 10 of the periodic table (IUPAC) or a compound of actinide or lanthanide, comprise a metal compound which is selected from one of the groups 1 to 3 of the periodic table (IUPAC), and—comprise solid material, wherein the solid material does not comprise catalytically active sites, has a specific surface area below 500 m2/g, and has a mean particle size below 100.

Abstract: The invention refers to a process for preparing a Group 2 metal/transition metal olefin polymerization catalyst component in particulate form having improved polymerization properties due to the use of H2 during catalyst component preparation and the use of such catalyst components in a process for polymerizing olefins.

Abstract: The invention refers to a process for preparing a Group 2 metal/transition metal olefin polymerization catalyst component in particulate form having improved polymerization properties due to the use of H2 during catalyst component preparation and the use of such catalyst components in a process for polymerizing olefins.

Abstract: The invention is directed to a process for the manufacture of heterophasic propylene copolymer compositions comprising the steps of forming a propylene polymer matrix in at least one slurry reactor and optionally in at least one gas phase reactor and subsequently forming in at least one gas phase reactor an elastomeric copolymer by copolymerizing propylene with ethylene and/or with another alpha-olefin in the presence of said matrix, wherein the polymerization is carried out in the presence of a catalyst system comprising a catalyst in form of solid particles, said particles (a) have a surface area of less than 20 m2/g, (b) comprise a transition metal compound of groups 4 to 10 of the periodic table or a compound of actinide or lanthanide, (c) comprise a metal compound of groups 1 to 3 of the periodic table, and (d) comprise inclusions not comprising catalytically active sites.

Abstract: Process for the preparation of a catalyst being in the form of solid particles comprising the steps of preparing a solution of a complex of a metal which is selected from one of the groups 1 to 3 of the periodic table (IUPAC) and an electron donor by reacting a compound of said metal with said electron donor in an organic liquid reaction medium; adding to said solution solid material obtaining a suspension, said solid material does not comprise catalytically active sites, has a specific surface area below 500 m2/g, and has a mean particle size below 200 nm; combining said suspension at a temperature of at least 50° C.

Abstract: The invention refers to a process for preparing a Group 2 metal/transition metal olefin polymerization catalyst component in particulate form having improved polymerization properties due to the use of H2 during catalyst component preparation and the use of such catalyst components in a process for polymerizing olefins.

Abstract: Catalyst in form of solid particles, wherein the particles—have a specific surface area of less than 20 m2/g, comprise a transition metal compound which is selected from one of the groups 4 to 10 of the periodic table (IUPAC) or a compound of actinide or lanthanide, comprise a metal compound which is selected from one of the groups 1 to 3 of the periodic table (IUPAC), and—comprise solid material, wherein the solid material • does not comprise catalytically active sites, • has a specific surface area below 500 m2/g, and • has a mean particle size below 100.